Results 101 to 110 of about 49,566 (218)

Características clínicas, demográficas e epidemiológicas dos pacientes com hepatite B em seguimento em hospital universitário no sudeste do Brasil: predominância de casos HBeAg negativos [PDF]

, 2011
INTRODUCTION: Hepatitis B is common in Brazil, although there are regional differences regarding the degree of endemicity, the most frequent forms of transmission and the presence of different evolutive stages of chronic disease.
ALMEIDA FILHO, Luiz Carlos de, CHACHÁ, Silvana Gama Florencio, COSTA, Tarciana Vieira, FERREIRA, Sandro da Costa, FIGUEIREDO, José Fernando de Castro, MARTINELLI, Ana de Lourdes Candolo, PASSOS, Afonso Dinis da Costa, RAMALHO, Leandra Naira, SOUZA, Fernanda Fernandes, TEIXEIRA, Andreza Correa, VILLANOVA, Márcia Guimarães, ZUCOLOTO, Sérgio   +11 more
core   +2 more sources

An HBV‐Derived Peptide Poly6 as a Novel Candidate for Functional Cure Via IFN‐I–Mediated Epigenetic Regulation of cccDNA

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
ABSTRACT Covalently closed circular DNA (cccDNA) represents the central obstacle to achieving a functional cure for chronic hepatitis B virus (HBV) infection. Poly6, a peptide encoded within the HBV genome, was investigated for antiviral efficacy in hepatocyte‐derived cell lines, hydrodynamic injection models, and HBV transgenic mice.
Junghwa Jang, Dong Hyun Kim, Ziyun Kim, Eunseo Kim, Yu‐Min Choi, Bum‐Joon Kim   +5 more
wiley   +1 more source

Effect of HBeAg/anti-HBe coexistence on HBeAg seroconversion in treatment-naïve chronic hepatitis B patients with peginterferon-α

Therapeutic Advances in Gastroenterology
Background: As an uncommon serological pattern, the effect of hepatitis B e antigen/anti-hepatitis B e (HBeAg/anti-HBe) coexistence on peginterferon-α (Peg-IFN-α) therapy in patients with chronic hepatitis B (CHB) remains unknown.
Kaimin Song, Huitong Wang, Dawu Zeng, Yunyun Qian, Zhixiang Guo, Huatang Zhang, Yijuan Zheng, Yongjun Zhou, Xueping Yu, Zhijun Su   +9 more
doaj   +1 more source

Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area

Scientific Reports, 2017
To elucidate the impact of a hepatitis B (HB) vaccination program on the prevalence of HB surface antigen (HBsAg) and HB envelope antigen (HBeAg) as well as the success rate of HBeAg clearance among parturients, we collected data on parturients who gave ...
Chen-Hsuan Wu, Te-Yao Hsu, Fu-Tsai Kung, Chan-Chao ChangChien, Ching-Chang Tsai, Sheng-Nan Lu   +5 more
doaj   +1 more source

Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice

Annals of Hepatology, 2014
Background and aims. Entecavir (ETV) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established.Material and methods.
Ezequiel Ridruejo, Sebastián Marciano, Omar Galdame, María V. Reggiardo, Alberto E. Muñoz, Raúl Adrover, Daniel Cocozzella, Nora Fernandez, Claudio Estepo, Manuel Mendizabal, Gustavo A. Romero, Diana Levi, Teresa Schroder, Silvia Paz, Hugo Fainboim, Oscar G. Mandó, Adrián C. Gadano, Marcelo O. Silva   +17 more
doaj   +1 more source

Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now [PDF]

, 2015
Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver
Cuestas, María Luján, Eguibar, Nair, Gonzalez, Rodrigo Horacio, Nusblat, Alejandro David, Perazzo, Priscila   +4 more
core   +1 more source

Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA

Medicine, 2017
This study aimed to investigate the correlation between quantitative hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA levels, and to determine whether semiquantitative measurement of HBeAg can indicate the extent of HBV replication in HBeAg ...
Ping Chen, Qinfen Xie, Xuan Lu, Chengbo Yu, Kaijin Xu, B. Ruan, H. Cao, Hainv Gao, Lanjuan Li   +8 more
semanticscholar   +1 more source

Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi [PDF]

, 2006
Background Hepatitis B virus (HBV) genotypes have distinct geographic distribution. Moreover, much genetic variability has been described in the precore (PC) and basal core promoter (BCP) regions of the HBV genome.
Zaigham Abbas, Rana Muzaffar, Arif Siddiqui, Syed Ali Anwar Naqvi, Syed Adibul Hassan Rizvi, WM Lee, H Okamoto, H Norder, L Stuyver, P Arauz-Ruiz, H Norder, M Lindh, C Westland, AS Lok, F Rodriguez-Frias, C Grandjacques, CM Hunt, EV Buckwold, H Okamoto, K Takahashi, M Kurosaki, VE Buckwold, K Moriyama, K Kidd-Ljunggren, H Naito, M Hussain, MF Yuen, GL Wong, SS Gandhe, A Kumar, JH Kao, E Sablon, A Erhardt, A Ciancio, AS Lok, S Locarnini, J Summers, MR Brunetto, G Pastore, TJ Liang, S Shiina, E Orito, K Takahashi, S Sato, HL Chan, JH Kao, ZL Fang, M Baptista, M Sterneck, YK Chun, R Fukuda, M Lindh, S Gunther, AM Bozdayi, F Zoulim, F Davidson   +55 more
core   +2 more sources

HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene

Scientific Reports, 2017
Chronic HBV infection is a major cause of hepatocellular carcinoma (HCC). The association between hepatitis B “e” antigen (HBeAg) and HCC is well-established by epidemiological studies.
J. Samal, M. Kandpal, P. Vivekanandan
semanticscholar   +1 more source

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance

MedComm, Volume 7, Issue 4, April 2026.
Chronic hepatitis B patient (CHB) presents a challenge due to immune tolerance toward HBV surface antigen (HBsAg). This study aimed to achieve a functional cure by disrupting HBV tolerance through immunotherapy. CHB received standard NA therapy, or NA combined with IFN‐α, while a third group received the THRIL‐GM‐Vac regimen.
Shuang Geng, Feifei Yang, Hongyu Jia, Gan Zhao, Weidong Zhao, Jie Yu, Haoxiang Zhu, Huan Cai, Lishan Yang, Shuren Zhang, Fang Yu, Xiang Jin, Shijie Zhang, Xianzheng Wang, Yida Yang, Jiming Zhang, Bin Wang   +16 more
wiley   +1 more source